Rong Xu

Rong Xu has extensive work experience in the biotechnology and pharmaceutical industries. In 2005, Rong Xu joined Pfizer as a Senior Research Scientist, where they worked until 2009. From 2009 to 2020, they held positions at Profectus BioSciences, Inc, including Director of Immunology and Principal Research Scientist. In 2020, Rong Xu moved to the Sabin Vaccine Institute as Vice President of Non-Clinical Development, and later as Vice President of Research and Development until 2021. In 2021, they joined Clover Biopharmaceuticals as Senior Vice President of Pre-clinical R&D, and then as Senior Vice President of Vaccine Research until 2022. Currently, Rong Xu is the Chief Scientific Officer at Delonix Bioworks Ltd.

Rong Xu began their education by earning a Doctor of Medicine (MD) degree from Peking University Health Science Center from 1986 to 1991. Rong then pursued a Ph.D. in Immunology at Weizmann Institute of Science from 1996 to 2001. Xu furthered their education with a post-doctor training program in Immunology at HHMI at University of Washington from 2001 to 2004.